利妥昔单抗在重症皮肤病中的应用进展  

Rituximab Use in Severe Skin Diseases

作　　者：张佩莲 叶建州[1] ZHANG Peilian;YE Jianzhou(Hospital of Traditional Chinese Medicine Dermatology,Yunnan Provincial Hospital of Traditional Chinese Medicine,Kunming 650021,China)

机构地区：[1]云南省中医医院中医皮肤病专科医院,云南昆明650021

出　　处：《中国皮肤性病学杂志》2023年第2期240-244,共5页The Chinese Journal of Dermatovenereology

基　　金：云南省“万人计划”名医专项(YNWR-MY-2018-004)。

摘　　要：免疫性疱病、结缔组织病、血管炎等疾病属于皮肤科中的重症、难治性皮肤病。近年来,多种生物制剂和靶向治疗陆续应用于上述疾病中。目前在美国与欧洲,利妥昔单抗已作为中重度寻常型天疱疮、ANCA相关性血管炎的一线治疗方案。本文将对利妥昔单抗治疗上述疾病的作用机制、治疗方案以及安全性等方面做一概述。Autoimmune bullous diseases, connective tissue disease, vasculitis and other diseases belong to severe and refractory skin diseases in dermatology. In recent years, a variety of biological agents and targeted therapy have been used in the above diseases. Currently, in the United States and Europe, rituximab has been used as a first-line treatment for moderate to severe pemphigus vulgaris and ANCA-associated vasculitis. This article will give an overview of the mechanism of action, treatment options and safety of rituximab in the treatment of the above diseases.

关 键 词：利妥昔单抗 红斑狼疮 皮肌炎 系统性硬皮病 天疱疮 类天疱疮 血管炎 

分 类 号：R751[医药卫生—皮肤病学与性病学]